2020 Maryland Statutes
Criminal Law
Title 5 - Controlled Dangerous Substances, Prescriptions, and Other Substances
Subtitle 4 - Schedules
Section 5-402 - Schedule I

    (a)    Schedule I consists of each controlled dangerous substance:

        (1)    listed in this section;

        (2)    added to Schedule I by the Department under § 5–202(b) of this title; or

        (3)    designated as a Schedule I controlled dangerous substance by the federal government unless the Department objects under § 5–202(f) of this title.

    (b)    Unless specifically excepted under this subtitle or listed in another schedule, any of the following opiates, including their isomers, including optical and geometric isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation, are substances listed in Schedule I:

        (1)    acetyl–alpha–methylfentanyl (N–[1–(1–methyl–2–phenethyl)–4–piperidinyl]–N–phenylacetamide);

        (2)    acetylmethadol;

        (3)    acetyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacetamide);

        (4)    Acryl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacrylamide;

        (5)    AH–7921 (3,4–dichloro–N–[(1–dimethylamino) cyclohexylmethyl]) benzamide;

        (6)    allylprodine;

        (7)    alphacetylmethadol, except levo–alphacetylmethadol;

        (8)    alphameprodine;

        (9)    alphamethadol;

        (10)    alpha–methylfentanyl (N–[1–(alpha–methyl–beta–phenyl)ethyl–4–piperidyl] propionanilide; 1–(1–methyl–2–phenylethyl)–4–(N–propanilido) piperidine);

        (11)    alpha–methylthiofentanyl (N–[1–methyl–2–(2–thienyl)ethyl–4–piperidinyl]–N–phenylpropanamide);

        (12)    benzethidine;

        (13)    betacetylmethadol;

        (14)    beta–hydroxyfentanyl (N–[1–(2–hydroxy–2–phenethyl)–4–piperidinyl]–N–phenylpropanamide);

        (15)    beta–hydroxy–3–methylfentanyl;

        (16)    N–[1–[2–hydroxy–2–(thiophen–2–yl)ethyl]piperidin–4–yl]–N–phenylpropionamide;

        (17)    betameprodine;

        (18)    betamethadol;

        (19)    betaprodine;

        (20)    butyryl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylbutyramide);

        (21)    clonitazene;

        (22)    dextromoramide;

        (23)    diampromide;

        (24)    diethylthiambutene;

        (25)    difenoxin;

        (26)    dimenoxadol;

        (27)    dimepheptanol;

        (28)    dimethylthiambutene;

        (29)    dioxaphetyl butyrate;

        (30)    dipipanone;

        (31)    ethylmethylthiambutene;

        (32)    etonitazene;

        (33)    etoxeridine;

        (34)    4–Fluoroisobutyryl fentanyl (N–(4–fluorophenyl)–N–(1–phenethylpiperidin–4–yl)isobutyramide;

        (35)    furanyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylfuran–2–carboxamide);

        (36)    furethidine;

        (37)    hydroxypethidine;

        (38)    ketobemidone;

        (39)    levomoramide;

        (40)    levophenacylmorphan;

        (41)    3–methylfentanyl (N–[3–methyl–1–(2–phenylethyl)–4–piperidyl]–N–phenylpropanamide);

        (42)    3–methylthiofentanyl;

        (43)    morpheridine;

        (44)    MPPP (1–methyl–4–phenyl–4–propionoxypiperidine);

        (45)    mt–45 (1–cyclohexyl–4–(1,2–diphenylethyl)piperazine);

        (46)    noracymethadol;

        (47)    norlevorphanol;

        (48)    normethadone;

        (49)    norpipanone;

        (50)    ocfentanil (N–(2–fluorophenyl)–2–methoxy–N–(1–phenethylpiperidin–4–yl)acetamide);

        (51)    para–fluorofentanyl (N–(4–fluorophenyl)–N–[1–(2–phenethyl)–4–piperidinyl] propanamide;

        (52)    PEPAP (1–(–2–phenethyl)–4–phenyl–4–acetoxypiperidine);

        (53)    phenadoxone;

        (54)    phenampromide;

        (55)    phenomorphan;

        (56)    phenoperidine;

        (57)    piritramide;

        (58)    proheptazine;

        (59)    properidine;

        (60)    propiram;

        (61)    racemoramide;

        (62)    tetrahydrofuranyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenyltetrahydrofuran–2–carboxamide);

        (63)    thiofentanyl;

        (64)    tilidine;

        (65)    trimeperidine; and

        (66)    U–47700 (3,4–dichloro–N–[2–(dimethylamino)cyclohexyl]–N–methylbenzamide).

    (c)    Unless specifically excepted under this subtitle or listed in another schedule, any of the following opium derivatives, including their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, are substances listed in Schedule I:

        (1)    acetorphine;

        (2)    acetyldihydrocodeine;

        (3)    benzylmorphine;

        (4)    codeine methylbromide;

        (5)    codeine–N–oxide;

        (6)    cyprenorphine;

        (7)    desomorphine;

        (8)    dihydromorphine;

        (9)    drotebanol;

        (10)    etorphine (except hydrochloride salt);

        (11)    heroin;

        (12)    hydromorphinol;

        (13)    methyldesorphine;

        (14)    methyldihydromorphine;

        (15)    morphine methylbromide;

        (16)    morphine methylsulfonate;

        (17)    morphine–N–oxide;

        (18)    myrophine;

        (19)    nicocodeine;

        (20)    nicomorphine;

        (21)    normorphine;

        (22)    pholcodine; and

        (23)    thebacon.

    (d)    Unless specifically excepted under this subtitle or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, or that contains any of its salts, isomers, including optical, position, and geometric isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, is a substance listed in Schedule I:

        (1)    alpha–ethyltryptamine;

        (2)    4–bromo–2,5–dimethoxy–amphetamine;

        (3)    4–bromo–2,5–dimethoxyphenethylamine;

        (4)    2,5–dimethoxyamphetamine;

        (5)    2,5–dimethoxy–4–ethylamphetamine (DOET);

        (6)    2,5–dimethoxy–4–(n)–propylthiophenethylamine (2C–T–7);

        (7)    4–methoxyamphetamine (PMA);

        (8)    5–methoxy–3,4–methylenedioxy–amphetamine;

        (9)    4–methyl–2,5–dimethoxy–amphetamine;

        (10)    3,4–methylenedioxy amphetamine;

        (11)    3,4–methylenedioxymethamphetamine (MDMA);

        (12)    3,4–methylenedioxy–N–ethylamphetamine (MDA);

        (13)    N–hydroxy–3,4–methylenedioxyamphetamine;

        (14)    3,4,5–trimethoxyamphetamine;

        (15)    5–methoxy–N, N–dimethyltryptamine;

        (16)    alpha–methyltryptamine (AMT);

        (17)    bufotenine;

        (18)    diethyltryptamine (DET);

        (19)    dimethyltryptamine (DMT);

        (20)    5–methoxy–N, N–diisopropyltryptamine (5–MeO–DIPT);

        (21)    ibogaine;

        (22)    lysergic acid diethylamide;

        (23)    marijuana;

        (24)    mescaline;

        (25)    parahexyl–7374;

        (26)    peyote (meaning all parts of the plant presently classified botanically as Lophophora williamsii lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or extracts);

        (27)    N–ethyl–3–piperidyl benzilate;

        (28)    N–methyl–3–piperidyl benzilate;

        (29)    psilocybin;

        (30)    psilocyn;

        (31)    tetrahydrocannabinols;

        (32)    ethylamine analog of phencyclidine (N–ethyl–1–phenylcyclohexylamine);

        (33)    pyrrolidine analog of phencyclidine (1–(1–phenylcyclohexyl)–pyrrolidine);

        (34)    thiophene analog of phencyclidine (1–[1–(2–thienyl)–cyclohexyl]–piperidine);

        (35)    1–[1–(2–thienyl)cyclohexyl]pyrrolidine;

        (36)    4–methylmethcathinone (mephedrone);

        (37)    3, 4–methylenedioxypyrovalerone (MDPV);

        (38)    2–(2,5–dimethoxy–4–ethylphenyl) ethanamine (2C–E);

        (39)    2–(2,5–dimethoxy–4–methylphenyl) ethanamine (2C–D);

        (40)    2–(4–chloro–2,5–dimethoxyphenyl) ethanamine (2C–C);

        (41)    2–(4–iodo–2,5–dimethoxyphenyl) ethanamine (2C–I);

        (42)    2–[4–(ethylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–2);

        (43)    2–[4–(isopropylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–4);

        (44)    2–(2,5–dimethoxyphenyl) ethanamine (2C–H);

        (45)    2–(2,5–dimethoxy–4–nitro–phenyl) ethanamine (2C–N);

        (46)    2–(2,5–dimethoxy–4–(n)–propylphenyl) ethanamine (2C–P);

        (47)    3,4–methylenedioxy–N–methylcathinone (methylone);

        (48)    (1–pentyl–1H–indol–3–yl) (2,2,3,3–tetramethylcyclopropyl) methanone (UR–144);

        (49)    [1–(5–fluoro–pentyl)–1H–indol–3–yl](2,2,3,3–tetramethylcyclopropyl) methanone (5–fluoro–UR–144, XLR11);

        (50)    N–(1–adamantyl)–1–pentyl–1H–indazole–3–carboxamide (APINACA, AKB48);

        (51)    quinolin–8–yl 1–pentyl–1H–indole–3–carboxylate (PB–22);

        (52)    quinolin–8–yl 1–(5–fluoropentyl)–1H–indole–3–carboxylate (5–fluoro–PB–22);

        (53)    N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(4–fluorobenzyl)–1H–indazole–3–carboxamide (AB–FUBINACA);

        (54)    N–(1–amino–3, 3–dimethyl–1–oxobutan–2–yl)–1–pentyl–1H–indazole–3–carboxamide (ADB–PINACA);

        (55)    2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine (25I–NBOMe);

        (56)    2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine (25C–NBOMe);

        (57)    2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine (25B–NBOMe);

        (58)    marijuana extract (meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus cannabis, other than the separated resin, whether crude or purified, obtained from the plant);

        (59)    4–methyl–N–ethylcathinone (4–MEC);

        (60)    4–methyl–alpha–pyrrolidinopropiophenone (4–MePPP);

        (61)    alpha–pyrrolidinopentiophenone (alpha–PVP);

        (62)    1–(1,3–benzodioxol–5–yl)–2–(methylamino) butan–1–one (butylone);

        (63)    2–(methylamino)–1–phenylpentan–1–one (pentedrone);

        (64)    1–(1,3–benzodioxol–5–yl)–2–(methylamino) pentan–1–one (pentylone);

        (65)    4–fluoro–N–methylcathinone (flephedrone);

        (66)    3–fluoro–N–methylcathinone (3–FMC);

        (67)    1–(naphthalen–2–yl)–2–(pyrrolidin–1–yl)pentan–1–one (naphyrone);

        (68)    alpha–pyrrolidinobutiophenone (alpha–PBP);

        (69)    N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–1H–indazole–3–carboxamide (AB–CHMINACA);

        (70)    N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–pentyl–1H–indazole–3–carboxamide (AB–PINACA);

        (71)    [1–(5–fluoropentyl)–1H–indazol–3–yl](naphthalen–1–yl)methanone (THJ–2201); and

        (72)    N–(1–amino–3,3–dimethyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–1H–indazole–3–carboxamide (MAB–CHMINACA).

    (e)    Unless specifically excepted under this subtitle or listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances having depressant effects on the central nervous system, or that contains its salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, is a substance listed in Schedule I:

        (1)    gamma–hydroxybutyric acid (GHB);

        (2)    mecloqualone; and

        (3)    methaqualone.

    (f)    Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, or that contains its salts, isomers, or salts of isomers, is a substance listed in Schedule I:

        (1)    aminorex;

        (2)    N–benzylpiperazine (BZP);

        (3)    cathinone;

        (4)    fenethylline;

        (5)    methcathinone;

        (6)    (�)cis–4–methylaminorex ((�)cis–4,5–dihydro–4–methyl–5–phenyl–2–oxazolamine);

        (7)    N–ethylamphetamine; and

        (8)    N, N–dimethylamphetamine.

    (g)    Unless specifically excepted under this subtitle or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, or that contains their salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible within the specific chemical designation, is a substance listed in Schedule I:

        (1)    5–(1, 1–dimethylheptyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol (CP–47,497);

        (2)    5–(1,1–dimethyloctyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol (CP–47,497 C8 homolog);

        (3)    1–pentyl–3–(1–naphthoyl) indole (JWH–018 and AM678);

        (4)    1–butyl–3–(1–naphthoyl) indole (JWH–073);

        (5)    1–hexyl–3–(1–naphthoyl) indole (JWH–019);

        (6)    1–[2–(4–morpholinyl)ethyl]–3–(1–naphthoyl) indole (JWH–200);

        (7)    1–pentyl–3–(2–methoxyphenylacetyl) indole (JWH–250);

        (8)    1–pentyl–3–[1–(4–methoxynaphthoyl)] indole (JWH–081);

        (9)    1–pentyl–3–(4–methyl–1–naphthoyl) indole (JWH–122);

        (10)    1–pentyl–3–(4–chloro–1–naphthoyl) indole (JWH–398);

        (11)    1–(5–fluoropentyl)–3–(1–naphthoyl) indole (AM2201);

        (12)    1–(5–fluoropentyl)–3–(2–iodobenzoyl) indole (AM694);

        (13)    1–pentyl–3–[(4–methoxy)–benzoyl] indole (SR–19 and RCS–4);

        (14)    1–cyclohexylethyl–3–(2–methoxyphenylacetyl) indole 7008 (SR–18 and RCS–8); and

        (15)    1–pentyl–3–(2–chlorophenylacetyl) indole (JWH–203).

    (h)    (1)    In this subsection:

            (i)    “controlled dangerous substance analogue” means a substance:

                1.    that has a chemical structure substantially similar to the chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II; and

                2.    that has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous substance listed in Schedule I or Schedule II; but

            (ii)    “controlled dangerous substance analogue” does not include:

                1.    a controlled dangerous substance;

                2.    a substance for which there is an approved new drug application; or

                3.    a substance exempted for investigational use under § 506 of the Federal Food, Drug, and Cosmetic Act.

        (2)    To the extent intended for human consumption, each controlled dangerous substance analogue is a substance listed in Schedule I.

    (i)    The Department may not add a substance to Schedule I under § 5–202 of this title unless the Department finds:

        (1)    a high potential for abuse of the substance;

        (2)    no accepted medical use in the United States for the substance; and

        (3)    a lack of accepted safety for use of the substance under medical supervision.